OncologyPRO: The home of ESMO’s educational and scientific resources

From EAU 2022:
A database analysis suggests that overall survival may be adversely affected by the presence of pelvic lymphadenopathy in patients with stage N3 penile squamous cell cancer

From EAU 2022
Relugolix achieves profound castration faster than leuprolide for men with advanced prostate cancer and maintains this benefit for longer

From EAU 2022:
The STORM trial has found comparable acute toxicity with metastasis-directed therapy and a whole-pelvis radiotherapy regimen for men with oligorecurrent nodal prostate cancer

From EAU 2022:
A chart review has found no positive impact of BCG on disease progression in patients with non-muscle-invasive bladder cancer considered high risk as per the new European Association of Urology risk groups

From EAU 2022:
Incorporating multiparametric magnetic resonance imaging into active surveillance for early-stage prostate cancer can reduce the number of biopsies required in the first 3 years

From World GI 2022:
Research sheds light on the immunogenicity of microsatellite instability-high or mismatch repair-deficient colorectal cancer with concomitant BRAF V600E or RAS mutations

From World GI 2022:
Tucatinib plus trastuzumab regimen has achieved “clinically meaningful” activity in previously treated patients with HER2-positive metastatic colorectal cancer

From World GI 2022:
Frailty, as assessed by a novel scoring system, is associated with worse short-term outcomes after oesophagectomy for oesophageal cancer in patients aged 65 years and older